Spelling suggestions: "subject:"benign erostatic hyperplasia"" "subject:"benign erostatic hyperplasias""
11 |
Sexual (dys)function and benign prostate disease implications for health care decision-making /Kelly-Blake, Karen Denise. January 2008 (has links)
Thesis (Ph.D.)--Michigan State University. Dept. of Anthropology, 2008. / Title from PDF t.p. (viewed on July 7, 2009) Includes bibliographical references (p. 127-135). Also issued in print.
|
12 |
Evaluating diagnostic and treatment modalities in the management of benign prostatic hyperplasia in the Veterans Administration populationFernandes, Ancilla W. January 2000 (has links)
Thesis (M.S.)--West Virginia University, 2000. / Title from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).
|
13 |
Rôle de l'inflammation prostatique chronique dans le développement de l'hyperplasie bénigne de la prostate / Chronic prostatic inflammation and benign prostatic hyperplasiaRobert, Grégoire 15 December 2011 (has links)
Pas de résumé français / Pas de résumé anglais
|
14 |
Effects of isoflavones in patients with watchful waiting benign prostate hyperplasia. / 異黃酮素治療良性前列腺增生之療效 / Yi huang tong su zhi liao liang xing qian lie xian zeng sheng zhi liao xiaoJanuary 2009 (has links)
Han, Li. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 132-140). / Abstract and appendixes also in Chinese. / Chapter 1.1 --- BACKGROUND & SIGNIFICANCE OF THE STUDY --- p.1 / Chapter 1.2 --- STRUCTURE OF THE THESIS --- p.4 / Chapter 2.1 --- BPH --- p.6 / Chapter 2.1.1 --- PREVALENCE OF BPH --- p.6 / Chapter 2.1.2 --- IMPACT OF BPH SYMPTOMS ON PATIENTS --- p.9 / Chapter 2.1.2.1 --- CLINICAL SYMPTOMS OF BPH --- p.9 / Chapter 2.1.2.2 --- IMPACT OF CLINICAL SYMPTOMS ON QUALITY OF LIFE --- p.10 / Chapter 2.1.3 --- IMPACT OF BPH MEDICAL MANAGEMENT ON PATIENTS --- p.11 / Chapter 2.1.3.1 --- MEDICAL MANAGEMENT OF BPH --- p.11 / Chapter 2.1.3.2 --- SIDE EFFECTS OF PHARMACOLOGICAL AND SURGICAL THERAPIES --- p.15 / Chapter 2.1.4 --- USE OF COMPLEMENTARY AND ALTERNATIVE THERAPY AMONG BPH PATIENTS --- p.19 / Chapter 2.1.4.1 --- PREVALENCE --- p.19 / Chapter 2.1.4.2 --- REASONS FOR TURNING TO CAM --- p.20 / Chapter 2.2 --- ISOFLAVONES --- p.43 / Chapter 2.2.1 --- ISOFLAVONES FUNCTION --- p.43 / Chapter 2.2.1.1 --- STRUCTURE --- p.43 / Chapter 2.2.1.2 --- FOOD SOURCES --- p.45 / Chapter 2.2.2 --- APPLICATION OF ISOFLAVONES IN BPH --- p.46 / Chapter 2.2.2.1 --- DOCUMENTED MECHANISM OF BPH --- p.46 / Chapter 2.2.2.2 --- STUDIES IN VITRO --- p.47 / Chapter 2.2.2.3 --- STUDIES IN VIVO --- p.48 / Chapter 2.2.2.4 --- EPIDEMIOLOGIC EVIDENCE --- p.49 / Chapter 2.3. --- RESEARCH GAP IN HUMAN STUDY --- p.50 / Chapter 3.1 --- STUDY DESIGN --- p.51 / Chapter 3.2 --- AIM --- p.51 / Chapter 3.3 --- STUDY POPULATION --- p.52 / Chapter 3.3.1 --- INCLUSION CRITERIA --- p.52 / Chapter 3.3.2 --- EXCLUSION CRITERIA --- p.52 / Chapter 3.3.3 --- SAMPLE SIZE ESTIMATION --- p.53 / Chapter 3.4 --- RANDOMIZATION --- p.54 / Chapter 3.4.1 --- GENERATION THE RANDOM ALLOCATION SEQUENCE AND DETAILS OF RESTRICTION OF RANDOMIZATION --- p.54 / Chapter 3.4.2 --- IMPLEMENTATION OF RANDOMIZATION --- p.54 / Chapter 3.5 --- BLINDING --- p.55 / Chapter 3.5.1 --- WHO WERE BLINDED --- p.55 / Chapter 3.6 --- INTERVENTION --- p.55 / Chapter 3.6.1 --- STUDY MEDICATIONS AND DOSAGE --- p.55 / Chapter 3.6.2 --- STUDY REGIMEN --- p.56 / Chapter 3.7 --- DATA COLLECTION --- p.56 / Chapter 3.8 --- OUTCOME MEASUREMENTS --- p.58 / Chapter 3.8.1 --- PRIMARY OUTCOME --- p.58 / Chapter 3.8.1.1 --- UROFLOWMETRY: PEAK URINE FLOW RATE (QMAX) --- p.58 / Chapter 3.8.2 --- SECONDARY OUTCOMES --- p.59 / Chapter 3.8.2.1 --- BLADDER SCAN: POST-VOIDING RESIDUAL VOLUME (PVR) --- p.59 / Chapter 3.8.2.2 --- SYMPTOMS SCORE (IPSS) --- p.60 / Chapter 3.8.2.3 --- QUALIFY OF LIFE --- p.61 / Chapter 3.8.2.4 --- SERUM PSA LEVEL --- p.62 / Chapter 3.8.2.5 --- URINALYSIS TEST --- p.62 / Chapter 3.8.3 --- AE/SAE --- p.63 / Chapter 3.8.3.1 --- SELF REPORTED AE/SAE --- p.63 / Chapter 3.8.3.2 --- SEXUAL HORMONE LEVEL --- p.64 / Chapter 3.8.3.3 --- SEXUAL RELATED QUALITY OF LIFE --- p.64 / Chapter 3.9 --- STATISTICAL ANALYSIS --- p.65 / Chapter 3.9.1 --- DESCRIPTIVE ANALYSIS --- p.65 / Chapter 3.9.2 --- COMPARATIVE ANALYSIS --- p.65 / Chapter 4.1 --- PARTICIPANTS FLOW --- p.67 / Chapter 4.2 --- DEMOGRAPHICS --- p.69 / Chapter 4.3 --- BASELINE CHARACTERISTICS COMPARISON --- p.70 / Chapter 4.3.1 --- IPSS --- p.72 / Chapter 4.3.2 --- QMAX AND PRV --- p.73 / Chapter 4.3.3 --- QUALITY OF LIFE --- p.73 / Chapter 4.3.4 --- SERUM PSA LEVEL --- p.74 / Chapter 4.4 --- EFFICACY OUTCOMES --- p.74 / Chapter 4.4.1 --- QMAX AND PVR --- p.74 / Chapter 4.4.1.1 --- QMAX --- p.74 / Chapter 4.4.1.2 --- PVR --- p.75 / Chapter 4.4.2 --- IPSS --- p.79 / Chapter 4.4.2.1 --- TOTAL IPSS --- p.79 / Chapter 4.4.2.2 --- IPSS SUB SCORE 1_ INCOMPLETE EMPTYING --- p.79 / Chapter 4.4.2.3 --- IPSS SUB SCORE 2_ FREQUENCY --- p.80 / Chapter 4.4.2.4 --- IPSS SUB SCORE 3_INTERMITTENCY --- p.81 / Chapter 4.4.2.5 --- IPSS SUB SCORE 4_ URGENCY --- p.82 / Chapter 4.4.2.6 --- IPSS SUB SCORE 5_ WEAK STREAM --- p.82 / Chapter 4.4.2.7 --- IPSS SUB SCORE 6_ STRAINING --- p.83 / Chapter 4.4.2.8 --- IPSS SUB SCORE 7_ NOCTURIA --- p.84 / Chapter 4.4.3 --- QOL --- p.90 / Chapter 4.4.3.1 --- QOL IN IPSS Q8_QOL_URINATION --- p.90 / Chapter 4.4.3.2 --- QOL IN SF-36 --- p.91 / Chapter 4.4.3.2.1 --- PHYSICAL FUNCTIONING --- p.91 / Chapter 4.4.3.2.2 --- ROLE-PHYSICAL --- p.92 / Chapter 4.4.3.2.3 --- BODY PAIN --- p.92 / Chapter 4.4.3.2.4 --- GENERAL HEALTH --- p.93 / Chapter 4.4.3.2.5 --- VITALITY --- p.94 / Chapter 4.4.3.2.6 --- SOCIAL FUNCTIONING --- p.95 / Chapter 4.4.3.2.7 --- ROLE-EMOTIONAL --- p.95 / Chapter 4.4.3.2.8 --- MENTAL HEALTH --- p.96 / Chapter 4.4.4 --- SERUM PSA LEVEL --- p.103 / Chapter 4.4.5 --- SUBGROUP ANALYSIS --- p.106 / Chapter 4.4.6 --- SELF-PREFERENCE EFFECT ANALYSIS --- p.107 / Chapter 4.4.7 --- DIARY ANALYSIS --- p.109 / Chapter 4.5 --- ADVERSE EVENTS --- p.113 / Chapter 4.5.1 --- SELF-REPORTED AE/SAE --- p.113 / Chapter 4.5.2 --- SEXUAL HORMONE LEVEL --- p.114 / Chapter 4.5.3 --- SEXUAL RELATED QUALITY OF LIFE --- p.114 / Chapter 4.5.3.1 --- SEXUAL LIFE UNSATISFACTORY --- p.114 / Chapter 4.5.3.2 --- LIBIDO DECREASE --- p.115 / Chapter 5.1 --- PRINCIPAL FINDINGS --- p.116 / Chapter 5.1.1 --- EFFICACY --- p.116 / Chapter 5.1.2 --- SAFETY --- p.117 / Chapter 5.2 --- STRENGH AND LIMITATIOINS --- p.117 / Chapter 5.2.1 --- STRENGTH --- p.117 / Chapter 5.2.1.1 --- BLINDING IS EFFECTIVE --- p.117 / Chapter 5.2.1.2 --- COMPLIANCE IS GOOD --- p.118 / Chapter 5.2.1.3 --- LONG TREATMENT PERIOD --- p.119 / Chapter 5.2.1.4 --- STUDY OUTCOMES INCLUDE BOTH OBJECTIVE OUTCOMES AND SUBJECTIVE OUTCOMES --- p.121 / Chapter 5.2.2 --- LIMITATIONS --- p.121 / Chapter 5.2.2.1 --- INSUFFICIENT SAMPLE SIZE --- p.122 / Chapter 5.2.2.2 --- POSSIBLY LOW DOSE --- p.122 / Chapter 5.2.2.3 --- LACK OF BASELINE DATA ON QUALITY OF SEXUAL LIFE --- p.123 / Chapter 5.2.2.4 --- "LACK OF DATA ON LIFESTY FACTORES INCLUDING DIETARY HABIT, PHYSICAL ACTIVITY, SMOKING STATUS AND ACOHOL CONSUMPTION" --- p.123 / Chapter 5.3 --- INTERPRETATIONS OF THE RESUTLS --- p.124 / Chapter 5.3.1 --- TWO POSIVE RESULTS IN EMPTYING FUNCTION AND QUALITY OF LIFE --- p.124 / Chapter 5.3.2 --- ONE NEGATIVE RESULT IN PEAK URINARY FLOW RATE --- p.127 / Chapter 5.3.3 --- QUALITY OF SEXUAL LIFE --- p.129 / Chapter 6.1 --- CONCLUSIONS --- p.130 / Chapter 6.2 --- IMPLICATIONS --- p.131
|
15 |
Prostat kanserli hastalarda leptin düzeylerinin araştırılması /Dilmen, Cem. Perk, Hakkı. January 2004 (has links) (PDF)
Tez (Tıpta Uzmanlık) - Süleyman Demirel Üniversitesi, Tıp Fakültesi, Üroloji Anabilim Dalı, 2004. / Bibliyografya var.
|
16 |
Estudo comparativo entre a administração de toxina botulínica “A” e a orquiectomia no tratamento da hiperplasia prostática benigna do cãoMostachio, Giuliano Queiroz [UNESP] 22 February 2008 (has links) (PDF)
Made available in DSpace on 2014-06-11T19:23:43Z (GMT). No. of bitstreams: 0
Previous issue date: 2008-02-22Bitstream added on 2014-06-13T18:48:32Z : No. of bitstreams: 1
mostachio_gq_me_jabo.pdf: 1253600 bytes, checksum: c1f946210aa85f9b2c8aa26f7af6e985 (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, sendo que 80% dos cães com cinco anos apresentam evidências histológicas de sua presença. A fisiopatologia da doença não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado na próstata, mostrando que esta induz atrofia do parênquima e redução do volume. Como o cão é o único animal doméstico que apresenta esta alteração, este se apresenta como modelo experimental para novos estudos da HPB humana. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da TB-A sobre a próstata, libido e qualidade do sêmen, comparando os dados com animais orquiectomizados. Para tanto, 18 cães adultos, com evidências ultra-sonográficas de HPB foram submetidos à castração ou administração de 250 ou 500 U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento para a HPB, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações significativas na libido, ereção ou qualidade e características seminais. Efeitos locais e sistêmicos também não foram observados. Administração de 250 U da TB-A promoveu redução máxima de 9,4% do volume prostático, entretanto, tal redução não foi significativa. Por outro lado, a administração de 500 U de TB-A reduziu significamente as variáveis comprimento, altura e volume da próstata. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina. / Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 – 2 years. 80% of 5 years-old dogs have histologic evidences of BPH. Despite the little knowledge concerning about this disease, dihydrotestosterone is the main involved hormone. Recently, the effect of botulinum toxin A (BT-A) on rat and human prostate was investigated, and prostatic parenchyma atrophy and decrease in glandular volume were observed. The dog is one of a few animals that can develop BPH spontaneously and is frequently used as an animal model for human prostatic hyperplasia. Based on that, this study aimed to provide information on BT-A effects on prostate, libido and semen quality, in comparison to orchiectomized dogs. For that, 18 adults dogs, with Ultrasonographic evidences of BPH were submitted to orchiectomy or administration of 250 or 500 U of BT-A, and evaluated along 16 weeks. Orchiectomy presented excellent results on BPH, reducing the prostate volume up to 80%. Administration of BT-A did not significantly interfered on libido, erection or semen characteristics. Local and systemic effects also were not observed. Administration of 250 U of BT-A has promoved a maximum decrease of 9,4% on prostatic volume. However, this reduction was not statistically significant. On the other hand, 500 U of BTA administration has shown to significantly reduce the length, height and volume of prostate. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate.
|
17 |
Avaliação do valor diagnóstico e prognóstico do carboidrato L-fucose e das fucosiltransferases 3 e 6 em tumores prostáticos humanoVASCONCELOS, Juliana Lúcia de Albuquerque January 2012 (has links)
Submitted by Caroline Falcao (caroline.rfalcao@ufpe.br) on 2017-04-04T19:33:58Z
No. of bitstreams: 2
license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5)
2012-Dissertação-JulianaVasconcelos.pdf: 1176748 bytes, checksum: bb96bcabc13f8fef386568e90cfdc033 (MD5) / Made available in DSpace on 2017-04-04T19:33:58Z (GMT). No. of bitstreams: 2
license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5)
2012-Dissertação-JulianaVasconcelos.pdf: 1176748 bytes, checksum: bb96bcabc13f8fef386568e90cfdc033 (MD5)
Previous issue date: 2012 / Câncer é um conjunto de alterações celulares, que leva a uma divisão celular sem controle, podendo invadir tecidos adjacentes através da circulação sanguínea e do sistema linfático. O Câncer de Próstata (CP) é o segundo tumor mais comum entre a população masculina, e é considerado o câncer da terceira idade. A carcinogênese é um mecanismo complexo no qual ocorre mudanças na expressão de proteínas e glicoconjugados. Glicosilação é mediada por glicosiltransferases, enzimas que tem função de inserir resíduos de carboidratos específicos, e é um dos mais importantes processos biológicos pós-tradução de modificações na estrutura final e função de lipídios e proteínas. As fucosiltransferases (FUT) participam da transferência de resíduos de L-fucose, um sacarídeo associado ao câncer e a processos inflamatórios, da GDP-L-fucose. Neste estudo objetivou-se avaliar a expressão dos genes FUT3 e FUT6 através da Imunohistoquímica em Adenocarcinoma Prostático e Hiperplasia Prostática Benigna correlacionando com o padrão de expressão de L-fucose empregando a histoquímica com as lectinas UEA-I (Ulex europaeus) e LTA (Lotus tetragonolobus). As enzimas FUT3 e FUT6 apresentaram-se com uma alta expressão tanto no Adenocarcinoma Prostático como na Hiperplasia Benigna Prostática, principalmente a FUT 6. Os resultados da histoquímica com lectinas mostraram uma baixa distribuição/accessibilidade de L-fucose.
Sugere-se que, as enzimas FUT3 e FUT6 possam representar potenciais biomarcadores para avaliar alterações benignas e malignas prostáticas refletindo uma variação no perfil de L-fucose nestes tumores que podem estar associados às suas características biológicas. / Cancer is a set of cellular changes, leading to uncontrolled cell division that may
invade surrounding tissues via bloodstream and lymphatic system. Prostate
Cancer (PC) is the second most common tumor in men and is considered the
cancer of the elderly. Carcinogenesis is a complex mechanism in which
changes occur in the expression of proteins and glycoconjugates where
glycosylation plays key roles since modulates the carbohydrate moieties in
glycoconjugates being one of the most important biological processes of posttranslational
modifications in the final structure and function of lipids and
proteins. Fucosyltransferases (FUTs) are enzymes that catalyze the transfer of
the L-fucose residues, a saccharide which has been linked to cancer and
inflammation features, from GDP-Fuc. This study the objective to evaluate the
expression of genes FUT 3 and FUT 6 by immunohistochemistry in Prostatic
Adenocarcinoma and Benign Prostatic Hyperplasia and to correlates with the
expression pattern of L-fucose using lectin histochemistry with UEA-I (Ulex
europaeus) and LTA (Lotus tetragonolobus). FUT3 and FUT6 showed a high
expression in both prostatic tissues, especially FUT6. The results of lectin
histochemistry showed a low distribution/accessibility of L-fucose residues. It is
suggested that FUT3 and FUT6 may represent potential biomarkers to evaluate
benign and malignant alterations in prostate reflecting a variation in the profile
of L-fucose residues in these tumors which can be associated to their biological
features.
|
18 |
Abordagem quantitativa da expressão do gene WFDC1 e sua isoforma delta 3 = Quantitative approach of the expression of WFDC1 gene and its isoform delta 3 / Quantitative approach of the expression of WFDC1 gene and its isoform delta 3Almeida Neto, Adauto, 1977- 25 August 2018 (has links)
Orientadores: Hernandes Faustino de Carvalho, Paulo Roberto Eleutério de Souza / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-25T14:18:25Z (GMT). No. of bitstreams: 1
AlmeidaNeto_Adauto_D.pdf: 4167026 bytes, checksum: ca3afd135b583810d6996e33016f9e69 (MD5)
Previous issue date: 2014 / Resumo: A próstata é alvo de afecções severas que comprometem a função urinária, a qualidade de vida e que consistem em risco de vida aos indivíduos do sexo masculino, particularmente com o avançar da idade. Interações dinâmicas entre o epitélio prostático e o estroma, regulam vários aspectos do desenvolvimento, da função e das patologias prostáticas. O gene WFDC1 é expresso pelas células musculares lisas do estroma prostático normal e tem função na regulação do comportamento do epitélio, na organização da matriz extracelular e na regulação da angiogênese. Dois transcritos principais são oriundos de splicing alternativo do transcrito primário: um com todos os éxons (WFDC1) e outro sem o éxon 3 (Delta 3). Neste trabalho, investigamos as relações quantitativas entre estas duas variantes, com emprego de qRT-PCR (Taqman) e sondas para as junções dos éxons 2-3 e 2-4, em amostras de hiperplasia prostática benigna (BPH) e de câncer de próstata (PCA) provenientes de bancos de tecidos. A expressão do gene marcador MYH11 foi utilizada como estimativa do conteúdo de células musculares lisas nas amostras. Os resultados demonstraram que as amostras puderam ser dividas em dois grupos com expressão diferencial da MYH11(um com baixa expressão e outro com alta miosina, sendo o primeiro correspondente ao quartil inferior da distribuição dos valores de expressão). Foi demonstrada correlação entre a expressão de WFDC1 e MYH11 em BPH, mas não em PCA, enquanto não houve correlação entre Delta 3 e WFDC1 e nem com MYH11. O conteúdo de Delta 3 variou em cinco ordens de magnitude em comparação ao de WFDC1. A razão entre as duas variantes apresentou variação exponencial, distribuições discretas e intercaladas das amostras de BPH e de PCA, que se distribuíram em populações que preservaram as relações 10:1; 1:1 e 1:3. Poucas amostras estiveram livres de cada uma destas variantes. Em conclusão, a expressão do gene WFDC1 e de sua variante WFDC1 correlaciona-se com a diferenciação das células musculares lisas, mas não está condicionada a ela, enquanto a expressão de Delta 3 é completamente independente deste parâmetro e tem correlação positiva com o progressão do PCA, quando o sistema de classificação de Gleason (Gleason 1 + Gleason 2) foi considerado. Adicionalmente, fatores independentes da idade, incidência de BPH ou PCA, são mais influentes na determinação da quantidade total e da proporção entre as duas variantes / Abstract: The prostate gland is intimately related with reproductive and urinary functions, commonly disturbed by a series of diseases. Besides reducing the quality of life, they consist in serious life risk particularly to the aging men. Dynamic interactions between the epithelium and stroma in the gland regulate various aspects of development, function and pathologies. The WFDC1 gene is expressed by smooth muscle cells in the prostate stroma and its product ps20 was shown to control epithelial cell behavior, extracellular matrix organization and angiogenesis. It is supposed to function as a serine protease inhibitor, as other members of its family do. Two transcripts are produced as a result of alternative splicing. The first (WFDC1) retains all exons and the second (Delta 3) lacks the exon 3. In this work, we investigated the quantitative relationship among these two splicing variants, using qRT-PCR (Taqman) probing the junctions between exons 2-3 and 2-4, in benign prostatic hyperplasia (BPH) and prostate cancer (PCA) samples from tissue banks. The expression of the MYH11 gene was used to estimate the content of smooth muscle cells in the samples. The results demonstrate that the samples could be divided in two groups with low or high expression of MYH11, the first corresponding to the lower quartile of expression values). WFDC1 and MYH11 expression were correlated in the BPH samples. Delta 3 expression was independent of both WFDC1 and from WFDC1. The ratio between the variants WFDC1 and Delta 3 varied exponentially in five orders of magnitude. The the ratio between the two variants also varied exponentially, with BPH and PCA samples arranged in discrete and intercalated subgroups. The distribution of populations with different expression levels preserved the ratios 10:1, 1:1 and 1:3. Either variant was absent in only a few samples. In conclusion, the expression of WFDC1 and it WFDC1 variant correlates with but is not conditioned to the differentiation of smooth muscle cells, while Delta 3 is completely independent and is positively correlated with PCA grade (as assessed by the summed Gleason score). Unknown factors independent of age, BPH or PCA incidence are likely influencing Delta 3 expression / Doutorado / Biologia Celular / Doutor em Biologia Celular e Estrutural
|
19 |
Assessment of the anti-proliferative and anti-inflammatory pollen extract Cernitin™ in prostatic cells and isolated human peripheral blood mononuclear cellsLaguitan, Reuben Victor January 2021 (has links)
Benign prostatic hyperplasia (BPH) and chronic prostatitis (CP) are common diseases in aging men. Though medications are available to alleviate these conditions, problems of possible side-effects of first-line synthetic drugs for prostatic conditions have allowed patients to switch to a safer plant-based medication. CernitinTM, a pollen extract, is used to alleviate these conditions. A recent in vitro study showed that CernitinTM inhibits cell proliferation and induce a regulatory effect on inflammatory parameters. To validate those results, the inter-batch variability of CernitinTM was assessed using the active ingredients CernitinTM T60 and CernitinTM GBX on the human prostatic cell lines BPH‐1 and WPMY‐ 1 and on human peripheral blood mononuclear cells (hPBMCs) in vitro. Cell proliferation assay was performed in prostatic cell lines, while inflammatory parameters were analyzed in hPBMCs. Results revealed that both CernitinTM active ingredients, regardless of batch production, significantly inhibited the proliferation of both prostatic cell lines after 48 and 72 hours, respectively (p < 0.05 to p < 0.001). Among the batches, there were no significant differences observed. Notably, the GBX batches 14164, 14548 and 14160 had a more pronounced effect on cell proliferation right after 48 hours on both cell lines. Whilst, T60 batches 11539 and 14144 had a pronounced effect right after 48 hours on BPH cells. In hPBMC, the production of the anti-inflammatory cytokine interleukin (IL)- 10 and its receptor IL-10 receptor subunit beta (RB), as well as pro-inflammatory cytokine IL-6 was significantly increased after treatment with the T60 formulation regardless of the batch, but not after treatment with the GBX batch. Moreover, IL-10 receptor subunit alpha (RA) and tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL) expression increased after the use of both formulations (p < 0.05 to p < 0.001). The pro-inflammatory cytokine IL-8 and chemokine CXCL-10 was significantly decreased using both batches of T60 (p < 0.05 to p < 0.001). Collectively, these results support the claim of the role of CernitinTM as an anti-proliferative agent and as a cytokine regulator.
|
20 |
Machine Learning for Responsiveness of Medication in Bladder and Prostate SyndromesJu, Mingxuan 01 June 2020 (has links)
No description available.
|
Page generated in 0.114 seconds